- Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors
- Quest Diagnostics Declares Quarterly Cash Dividend
- Workforce Drug Test Cheating Surged in 2023, Finds Quest Diagnostics Drug Testing Index Analysis of Nearly 10 Million Drug Tests
- Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference
- Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer
- Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI
- Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
- Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
- Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
- Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
More ▼
Key statistics
On Thursday, Quest Diagnostics Inc (DGX:NYQ) closed at 142.43, -2.16% below its 52-week high of 145.58, set on Jul 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 140.77 |
---|---|
High | 142.95 |
Low | 140.41 |
Bid | 131.00 |
Offer | 145.00 |
Previous close | 140.78 |
Average volume | 740.07k |
---|---|
Shares outstanding | 111.09m |
Free float | 110.62m |
P/E (TTM) | 18.94 |
Market cap | 15.64bn USD |
EPS (TTM) | 7.43 USD |
Annual div (ADY) | 3.00 USD |
---|---|
Annual div yield (ADY) | 2.13% |
Div ex-date | Apr 05 2024 |
Div pay-date | Apr 22 2024 |
Data delayed at least 15 minutes, as of May 17 2024 00:00 BST.
More ▼